Ketoconazole
FDA-approved product (tablet, oral), marketed as Extina, Ketoconazole, Ketozole and 3 more.
- Registered studies
- 50+
- Lab records
- 1
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adrenal gland disease
- Blastomycosis
- Cushing syndrome
- Seborrheic dermatitis
- Tinea
- Tinea pedis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Imidazole and triazole derivatives; Imidazole derivatives; Anticorticosteroids
- FDA pharmacologic class
- Azole Antifungal FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC08; WHO ATC G01AF11; WHO ATC J02AB02; FDA class Azole Antifungal
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis81.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ketoconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels
NCT01749085 · start 2012-12
Registered record
- Registry ID
- NCT01749085
- Conditions
- Healthy Volunteers
- Interventions
- PF-04449913, ketoconazole; PF-04449913, ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2013-02
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionPF-04449913, ketoconazole; PF-04449913, ketoconazolePhasePhase 1Registry statusCompletedEffect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics
NCT01721070 · start 2012-11
Registered record
- Registry ID
- NCT01721070
- Conditions
- Pharmacokinetics
- Interventions
- Sufentanil NanoTab (SUF NT) 15 mcg; Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2012-12
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPharmacokineticsInterventionSufentanil NanoTab (SUF NT) 15 mcg; Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcgPhasePhase 1Registry statusCompletedPharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
NCT01454076 · start 2011-11-10
Registered record
- Registry ID
- NCT01454076
- Conditions
- Nonhematologic Malignancies; Lymphoma
- Interventions
- Ixazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole; Rifampin; Clarithromycin; Ixazomib 4 mg Capsule B
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-11-10
- Completion
- 2016-06-16
- Enrolment
- 112
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNonhematologic Malignancies; LymphomaInterventionIxazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole +3 morePhasePhase 1Registry statusCompletedA Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects
NCT01468714 · start 2011-10
Registered record
- Registry ID
- NCT01468714
- Conditions
- Human Volunteers
- Interventions
- PF-04937319 / ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2011-10
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman VolunteersInterventionPF-04937319 / ketoconazolePhasePhase 1Registry statusCompletedA Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
NCT01591850 · start 2011-09
Registered record
- Registry ID
- NCT01591850
- Conditions
- Healthy Volunteer
- Interventions
- RO5093151; atazanavir; ketoconazole; rifampicin; ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-09
- Completion
- 2011-11
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteerInterventionRO5093151; atazanavir; ketoconazole; rifampicin +1 morePhasePhase 1Registry statusCompletedA Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01363778 · start 2011-05
Registered record
- Registry ID
- NCT01363778
- Conditions
- Healthy
- Interventions
- tivozanib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2011-07
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventiontivozanibPhasePhase 1Registry statusCompletedA Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers
NCT02198170 · start 2011-02
Registered record
- Registry ID
- NCT02198170
- Conditions
- Healthy Volunteers
- Interventions
- ketoconazole-placebo; placebo-ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2011-06
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionketoconazole-placebo; placebo-ketoconazolePhasePhase 1Registry statusCompletedITT4 Intratesticular Hormonal Milieu in Man (ITT4)
NCT01215292 · start 2011-01
Registered record
- Registry ID
- NCT01215292
- Conditions
- Healthy Males
- Interventions
- Acyline; Testosterone gel; ketoconazole 400; Ketoconazole 800; Dutasteride; Anastrozole; Placebo ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2012-03
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy MalesInterventionAcyline; Testosterone gel; ketoconazole 400; Ketoconazole 800 +3 morePhasePhase 1 / Phase 2Registry statusCompletedA Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
NCT01240226 · start 2010-11
Registered record
- Registry ID
- NCT01240226
- Conditions
- Healthy Volunteer
- Interventions
- GDC-0941; GDC-0941; ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2010-12
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteerInterventionGDC-0941; GDC-0941; ketoconazolePhasePhase 1Registry statusCompletedA Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
NCT01114191 · start 2010-05
Registered record
- Registry ID
- NCT01114191
- Conditions
- Solid Tumors
- Interventions
- ABT-869; ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-05
- Completion
- 2011-02
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSolid TumorsInterventionABT-869; ketoconazolePhasePhase 1Registry statusCompletedA Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813
NCT01932320 · start 2010-02
Registered record
- Registry ID
- NCT01932320
- Conditions
- Healthy
- Interventions
- JNJ-40411813: Formulation A; JNJ-40411813: Formulation B; JNJ-40411813: Formulation C; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2010-05
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionJNJ-40411813: Formulation A; JNJ-40411813: Formulation B; JNJ-40411813: Formulation C; KetoconazolePhasePhase 1Registry statusCompletedTrial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649
NCT01154764 · start 2009-10
Registered record
- Registry ID
- NCT01154764
- Conditions
- Healthy
- Interventions
- CG100649; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-10
- Completion
- 2010-12
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCG100649; KetoconazolePhasePhase 1Registry statusCompletedValidation Study of Multiple Probe Compounds for Drug Interaction Evaluation
NCT00964106 · start 2009-08-26
Registered record
- Registry ID
- NCT00964106
- Conditions
- Drug Interactions
- Interventions
- Caffeine; Rosiglitazone; Flurbiprofen; Omeprazole; Dextromethorphan; Midazolam; Rosuvastatin; Ketoconazole; Fluconazole; Rifampin; Rosiglitazone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-08-26
- Completion
- 2011-08-29
- Enrolment
- 87
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug InteractionsInterventionCaffeine; Rosiglitazone; Flurbiprofen; Omeprazole +7 morePhasePhase 1Registry statusCompletedStudy Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)
NCT00914121 · start 2009-06
Registered record
- Registry ID
- NCT00914121
- Conditions
- Healthy Subjects
- Interventions
- SKI-606; Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-06
- Completion
- 2009-08
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionSKI-606; Placebo; MoxifloxacinPhasePhase 1Registry statusCompletedRelative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers
NCT02170675 · start 2009-06
Registered record
- Registry ID
- NCT02170675
- Conditions
- Healthy
- Interventions
- Dabigatran etexilate; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-06
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionDabigatran etexilate; KetoconazolePhasePhase 1Registry statusCompleted